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ABSTRACT
With the aim to obtain novel compounds possessing both strong affinity against human carbonic anhy-
drases and low toxicity, we synthesised novel thiourea and sulphonamide derivatives 3, 4 and 10, and
studied their in vitro inhibitory properties against human CA I, CA II and CA IX. We also evaluated the tox-
icity of these compounds using zebrafish larvae. Among the three compounds, derivative 4 showed effi-
cient inhibition against hCA II (KI ¼ 58.6 nM). Compound 10 showed moderate inhibition against hCA II
(KI ¼ 199.2 nM) and hCA IX (KI ¼ 147.3 nM), whereas it inhibited hCA I less weakly at micromolar concen-
trations (KI ¼ 6428.4 nM). All other inhibition constants for these compounds were in the submicromolar
range. The toxicity evaluation studies showed no adverse effects on the zebrafish larvae. Our study sug-
gests that these compounds are suitable for further preclinical characterisation as potential inhibitors of
hCA I, II and IX.
ARTICLE HISTORY
Received 27 September 2019
Revised 22 October 2019









Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes, present
in most of the living organisms and encoded by seven evolutionarily
unrelated gene families: the a-.b-.c-.d-.f-.g-. and h-CAs1. The CAs
catalyse the basic reaction of reversible hydration of carbon dioxide
to bicarbonate and proton2. This reaction is fundamental for bio-
chemical processes in all living organisms1,3. Invertebrates and
lower organisms contain all the seven members of CA gene families
and, in some cases, multiple gene families with in the same organ-
ism1. In contrast, vertebrates and mammals contain only a-CAs1. In
humans, the CAs regulate a broad range of physiological processes,
such as respiration, transport of carbon dioxide/bicarbonate
between the lung and metabolising tissues, pH homeostasis, and
electrolyte secretion in many tissues and organs2. There are 15 CA
isoforms in humans of which 12 are catalytically active. Three are
inactive due to the lack of one or more of the three-histidine resi-
dues required for enzymatic activity2–3. The human CA isoforms dif-
fer from one another in cellular localisation, distribution in organs,
levels of expression in tissues and their kinetic properties4–5. The
human CA isoforms have high sequence and structural similarities,
and therefore only subtle differences exist in their active sites6–7.
In humans, increased expression of CA isoforms is sometimes
associated with certain disease conditions2. The cytosolic hCA I
and II proteins have been linked to retinal and cerebral oedema,
glaucoma, epilepsy and altitude sickness2,4. hCA IX, a transmem-
brane CA isoform, is overexpressed under hypoxic conditions in
solid tumours and is involved in the progression of cancer8,9.
Many CA inhibitors have been used for treating various human
diseases2. Even if the inhibitors achieve desirable therapeutic
effects, they may cause unacceptable level of toxicity in
humans10,11, most probably due to the off-target effects attribut-
able to the inhibition of CA isoforms that are not involved in the
target disease or due to general toxic effects of the chemical12,13.
Therefore, to target particular therapeutic areas with minimal off-
target effects, inhibition of specific enzymes is necessary. Thus,
there is a particular need to develop inhibitors that are not only
selective against the human CAs but are also safe for clin-
ical use14.
Along this line, we have previously developed numerous
potent CA inhibitors that are not only effective against specific
human a-CAs and mycobacterial b-CAs, but also show minimal
toxicity and are suitable for developing further for clinical use as
drugs14–16. Recently, we reported sulphonamide and carbamate
compounds as hCA IX and mycobacterial b-CA inhibitors14–16. In
addition to the synthesis and in vitro and in vivo evaluation of
these compounds, we also tested them for safety and toxicity
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using 1–5 d post-fertilisation (dpf) zebrafish larvae. Our studies
showed that these inhibitors are safe for further preclinical charac-
terisation using in vivo models14–16.
In addition, in this study, we were interested in incorporating a
nitro-imidazole moiety as a privileged hypoxia sensitising scaffold
in the structure of CA inhibitors. The rationale was to investigate a
strategy of dual targeting (hypoxia and hCA IXn/hCA XII) in the
context of anticancer agents17. Previous results have shown the
validity of this approach when conjugation of 5-nitroimidazole
derivatives to CA inhibitors structures led to new radiosensitiser
agents targeting hypoxic tumours17–20. To further investigate the
effect and the influence of the 5-nitro imidazole moiety and
develop new potent and safer inhibitors, we have been continu-
ing our research on new inhibitors in the nitroimidazole series. In
the present study, we report the design, synthesis, in vitro CA
inhibition, and evaluation of toxicity of novel thiourea derivatives
3 and 4 and a sulphonamide derivative 10 using zebrafish larvae.
Materials and methods
Chemistry
All reagents and solvents were of commercial quality and used
without further purification unless otherwise specified. All reac-
tions were carried out under an inert atmosphere of nitrogen. TLC
analyses were performed on silica gel 60 F254 plates (Merck Art.
no. 1.05554). Spots were visualised under 254 nm UV illumination
or by ninhydrin solution spraying. Melting points were determined
on a B€uchi Melting Point 510 and are uncorrected. 1H and 13C
NMR spectra were recorded on Bruker DRX-400 spectrometer
using DMSO-d6 as solvent and tetramethylsilane as internal stand-
ard. For 1H NMR spectra, chemical shifts are expressed in d (ppm)
downfield from tetramethylsilane and coupling constants (J) are
expressed in Hertz. Electron ionisation mass spectra were recorded
in positive or negative mode on a Water MicroMass ZQ. All com-
pounds that were tested against purified physiological isoforms of
CAs were analysed by high-resolution ESI mass spectra (HRMS)
using on a Q-ToFI mass spectrometer fitted with an electrospray
ion source to confirm the purity of >95%.
1-(2-Isothiocyanatoethyl)-2-methyl-5-nitro-1H-imidazole (2):
Thiophosgene (1 equiv.) and sodium hydroxide (2 equiv.) were
added to a solution of 1 (0.5 equiv.) in chloroform and water (4:1)
at 0 C, and reaction mixture was warmed to room temperature.
Thin layer Chromatography confirmed complete disappearance of
the starting material. Reaction mixture was then washed with
water and extracted with DCM. The organic layer was dried over
anhydrous sodium sulphate, filtered and evaporated to get crude
compound which was purified by chromatography on silica gel
using ethyl acetate and petroleum ether as eluent with a gradient
from 5:5 to 9:1. Yield: 64%, 1H NMR (400MHz, DMSO-d6) d 8.10 (s,
1H), 4.65–4.60 (m, 2H), 4.17–4.12 (m, 2H), 3.35 (s, 3H). 13C NMR
(101MHz, DMSO-d6) d 151.80, 138.80, 133.65, 129.62, 45.06, 14.28.
MS (ESIþ) m/z 213.04 [MþH]þ.
4-(2-(3-(2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thioureido)e-
thyl)phenyl sulphamide (3): 4-(2-aminoethyl) aniline (1 equiv.) was
added to a solution of 2 (1 equiv.) in acetonitrile and allowed to
stir at room temperature overnight. Reaction mixture was washed
with water and extracted with ethyl acetate. The organic layer
was dried over anhydrous sodium sulphate, filtered and evapo-
rated under vacuum to get crude compound which was then
reacted as-is with sulphamoyl chloride (3 equiv.) in dimethylaceta-
mide (DMA). After stirring for one night at room temperature, the
mixture was diluted with ethyl acetate, and washed three times
with water. The organic layer was dried over anhydrous magne-
sium sulphate and concentrated under vacuum. The residue was
purified by chromatography on silica gel using methylene chlor-
ide-methanol 9:1 as eluent. Yield: 43%, 1H NMR (400MHz, DMSO-
d6) d 9.35 (s, 1H), 8.03 (s, 1H), 7.51 (s, 2H), 7.11 (d, J¼ 9.1, 4H),
7.01 (s, 2H), 4.41 (s, 2H), 3.81 (s, 2H), 2.68 (s, 2H), 2.36 (s, 3H). 13C
NMR (101MHz, DMSO-d6) d 151.98, 139.08, 138.13, 133.70,
133.45–133.11, 129.40, 118.95, 55.38, 45.93, 14.30. MS (ESIþ) m/z
428.12 [MþH]þ.
4-(2-(3-(2–(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl) thioureido)e-
thyl)phenyl sulphamate (4): The same protocol as for the synthesis
of compound 3 starting from 2. Yield: 60%, 1H NMR (400MHz,
DMSO-d6) d 8.03 (s, 1H), 7.95 (s, 2H), 7.58 (d, J¼ 38.2, 2H), 7.29 (d,
J¼ 8.5, 2H), 7.20 (d, J¼ 8.5, 2H), 4.42 (s, 2H), 3.82 (s, 2H), 2.77 (s,
2H), 2.36 (s, 3H). 13C NMR (101MHz, DMSO-d6) d 151.44, 148.56,
138.56, 137.61, 133.16, 129.77, 121.97, 45.39, 30.63, 13.75. MS
(ESIþ) m/z 429.10 [MþH]þ.
2-(2-Methyl-5-nitro-1H-imidazol-1-yl) ethyl methanesulphonate
(6): Methane sulphonylchloride (1.1 equiv.) was added dropwise to
a stirred solution of metronidazole, 5 (1 equiv.), triethylamine (2
equiv.) and DMAP (1.1 equiv.) in anhydrous methylene chloride at
0 C. The reaction mixture was allowed to warm to room tempera-
ture and stirred for overnight. The reaction mixture was diluted
with methylene chloride and washed with water and brine. The
organic layer was dried over anhydrous sodium sulphate, filtered
and evaporated to get crude compound which was used further
without purification. Yield: quantitative. 1H NMR (DMSO-d6,
400MHz) d 8.05 (s, 1H), 4.61 (t, J¼ 7.3, 2H), 3.51 (t, J¼ 7.3, 2H),
2.50 (s, 3H); 13C NMR (DMSO-d6, 101MHz) d 151.08, 138.18,
133.14, 47.09 (s, 1H), 14.09, 2.28. MS (ESIþ) m/z 281.97 [MþH]þ.
S-(2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl) ethanethioate (7):
Potassium thioacetate (2 equiv.) was added to a solution of 6 (1
equiv.) in anhydrous DMF and stirred at room temperature for
16 h. The reaction mixture was then diluted with ethyl acetate
and washed with water and brine. The organic layer was dried
over anhydrous sodium sulphate, filtered and concentrated under
vacuum to give thioacetate 7. Yield: 83%, 1H NMR (400MHz,
DMSO-d6) d 8.01 (s, 1H), 4.45 (t, J¼ 6.6, 2H), 3.27 (t, J¼ 6.6, 2H),
2.46 (s, 3H), 2.29 (s, 3H). 13C NMR (101MHz, DMSO) d 194.59,
151.25, 138.42, 132.92, 44.68, 30.32, 27.87. MS (ESIþ) m/z
230.06 [MþH]þ.
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethane-1-sulphonyl chloride
(9): A solution of 7 (1 equiv.) was treated with hydrogen peroxide
[35% w/w in water (6ml)] and acetic acid (7ml). The reaction mix-
ture was allowed to stir for 24 h at room temperature; the excess
hydrogen peroxide was quenched by addition of 10% Pd/C
(0.050 g). The mixture was filtered on celite, concentrated, and co-
evaporated with toluene. The obtained sulphonic acid was used
further without purification. The crude 2-(2-methyl-5-nitro-1H-imi-
dazol-1-yl) ethane-1-sulphonic acid 8 (1 equiv.) was suspended in
anhydrous DCM and a solution of phosgene in toluene (20% wt.,
3.5ml) and dry DMF (1ml) was added under argon atmosphere.
After 1 h an additional 1ml phosgene solution was added, and
the mixture was stirred for 2 h under same conditions. After pre-
cipitation, the reaction mixture was filtered to get pure compound
9 as solid. Yield: 66%, 1H NMR (400MHz, DMSO-d6) d 8.80 (s, 1H),
4.63 (t, J¼ 6.3, 2H), 2.92 (t, J¼ 6.3, 2H), 2.78 (s, 3H), 13C NMR
(101MHz, DMSO-d6) d 149.90, 138.05, 123.91, 48.67, 44.17, 12.13.
MS (ESIþ) m/z 236.00 [MþH]þ.
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethane-1-sulphonamide (10):
To a solution of compound 9 (1 equiv.) in toluene was added at
room temperature 0.5M solution of liq. ammonia in 1,4-dioxane
(2ml). After 1 h, the reaction mixture was filtered to afford pure
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compound as white solid. Yield: 68%, 1H NMR (400MHz, DMSO-
d6) d 8.03 (s, 1H), 7.39 (s, 2H), 4.63 (t, J¼ 7.0, 2H), 3.49 (t, J¼ 7.0,
2H), 2.49 (s, 3H). 13C NMR (101MHz, DMSO-d6) d 151.43, 138.36,
133.04, 53.08, 40.85, 13.94. MS (ESIþ) m/z 235.05 [MþH]þ.
In vitro inhibition studies
An Applied Photophysics stopped-flow instrument was used for
assaying the CA-catalyzed CO2 hydration activity
21. Phenol red (at
a concentration of 0.2mM) was used as an indicator, working at
the absorbance maximum of 557 nm, with 20mM Hepes (pH 7.5)
as buffer and 20mM Na2SO4 (for maintaining the ionic strength
constant), following the initial rates of the CA-catalysed CO2
hydration reaction for a period of 10–100 s. The CO2 concentra-
tions ranged from 1.7 to 17mM for the determination of the kin-
etic parameters and inhibition constants. For each inhibitor, at
least six traces of the initial 5–10% of the reaction were used for
determining the initial velocity. The uncatalysed rates were deter-
mined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1mM) were pre-
pared in distilled-deionized water, and dilutions up to 0.01 nM
were done thereafter with distilled-deionized water. Inhibitor and
enzyme solutions were pre-incubated together for 15min at room
temperature prior to assay to allow for the formation of the E-I
complex. The inhibition constants were obtained by non-linear
least-squares methods using PRISM 3 and represent the average
from at least three different determinations. CA isoforms were
recombinant ones obtained in house as reported earlier.
Toxicity evaluation
Inhibitors
The three compounds 3, 4 and 10 were designed and synthesised
with the purpose of developing them as inhibitors of human CAs.
Subsequently, all the three compounds were investigated in vitro
as inhibitors of human CA I, CA II and CA IX. These compounds
were dissolved in dimethyl sulphoxide (DMSO) (Sigma-Aldrich, St.
Louis, MO) to prepare 100mM stock solutions. Before start of each
experiment, the series of dilatation were made from the above
stock in an embryonic medium [5.0mM NaCl, 0.17mM KCl,
0.33mM CaCl2, 0.33mM MgSO4, and 0.1% w/v Methylene Blue
(Sigma-Aldrich, Darmstadt, Germany)]. Embryos after 1-day post
fertilisation were exposed the each of the diluted inhibi-
tor solution.
Maintenance of zebrafish
AB strains of wild-type adult zebrafish were maintained at 28.5 C
in an incubator15. For collecting embryos, 3–5 pairs of male and
female fish were set up overnight for breeding22. The next morn-
ing, from the overnight breeding tanks 1–2-h post fertilisation
(hpf) embryos were collected in a sieve and rinsed with embryonic
medium [5.0mM NaCl, 0.17mM KCl, 0.33mM CaCl2, 0.33mM
MgSO4, and 0.1% w/v Methylene Blue (Sigma-Aldrich, Darmstadt,
Germany)] and kept the collected embryos in an incubator at
28.5 C overnight. The toxicity evaluation studies of the inhibitors
were performed using the fish that were 24 hpf. All the zebrafish
experiments were performed at the zebrafish core facility,
Tampere University, Finland and according to the protocol used in
our laboratory22.
Ethical statement
Tampere University has an established zebrafish core facility
authorisation granted by the National Animal Experiment Board
(ESAVI/7975/04.10.05/2016). The experiments using developing
zebrafish embryos were performed according to the Provincial
Government of Eastern Finland Province Social and Health
Department Tampere Regional Service Unit protocol # LSLH-
2007–7254/Ym-23. Care was taken to ameliorate suffering by
euthanizing the 5 dpf larvae by prolonged immersion in a petri
dish containing an overdose of Tricaine (Sigma-Aldrich, St. Louis,
MO) before fixing in buffered formaldehyde for histochem-
ical analysis.
Determination of LC50
The LC50 values of the compounds 3, 4 and 10 were determined
using 1-dpf embryos exposed to 10–12 different inhibitor concen-
trations. For each concentration of the inhibitor, we used 30 1dpf
larvae13,22. In each group, the larvae were exposed to different
concentrations of the inhibitors that ranged from 12.5 mM to
3mM. The dose response curve (DRC) was calculated using DRM
of the DRC R package23. The control group was constituted of an
equal number of larvae not treated with any chemical and the lar-
vae that were treated with 1% of DMSO. Toxicological evaluation
studies were performed in 24-well plates (Corning V R Co-star V R
cell culture plates). In each well, we placed 1–2 1-dpf embryos in
1ml of embryonic medium containing a diluted inhibitor. For con-
trol groups, 1% DMSO diluted in either embryonic medium or
embryonic medium with no chemical compound. A minimum of
three sets of experiments were carried out for each inhibitor. The
mortality of the larvae was checked every 24 h until 5 d after
exposure to the inhibitors.
Phenotypic analysis of control and inhibitor treated larvae
We assessed the effect of inhibitors on the zebrafish larvae after
5 d of exposure to the drugs; we analysed eight observable
phenotypic parameters: (1) mortality, (2) hatching, (3) oedema, (4)
movement pattern, (5) yolk sack utilisation, (6) heartbeat, (7) body
shape and (8) swim bladder development, using a stereo micro-
scope and recorded the observations for each inhibitor treated
and control groups. The images of the developing larvae were
taken using a Lumar V1.12 fluorescence microscope attached to a
camera with a 1.5 lens (Carl Zeiss MicroImaging GmbH, G€ottingen,
Germany). The images were analysed with AxioVision software
versions 4.7 and 4.8 as described in our standard protocol for
assessment of toxicity and safety of the chemical compounds22.
Swim pattern analysis
The movement of the zebrafish larvae was tracked from day 4 of
exposure to these inhibitors. Similarly, detailed analysis of the
swim pattern of the larvae was performed at the end of day 5
after exposure to the inhibitors. For analyses of movement pat-
tern, about 10–15 the zebrafish larvae were placed in a 35mm 
15mm petri dish containing embryonic medium and the larvae
were allowed to settle in the petri dish for 1min. The movement
of the zebrafish larvae was observed under the microscope for
1min. A short video of about 1min was taken for each group of
larvae that were treated with 125 mM concentration. The swim pat-
terns were compared with the control group zebrafish larvae that
were not treated with any inhibitor.
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Histological studies
The histological analyses were done to check the effect of inhibi-
tors on the internal tissues of the larvae that were treated with
different concentrations of the inhibitors used in the study and
the control group larvae not treated with any inhibitor and the
larvae treated with 1% DMSO. After 5 d of exposure to different
concentration of the inhibitors, the larvae were washed with phos-
phate buffered saline (PBS) immersed in excess amounts of
Tricaine to anaesthetize the larvae. The larvae thus prepared were
transferred to a 1.5ml microcentrifuge tube and fixed in buffered
formaldehyde (formaldehyde solution 4%, pH 6.9) in PBS for 3 h at
room temperature or overnight at 4 C. After the fixation, the lar-
vae were transferred to 70% ethanol and stored at 4 C before
being embedded in paraffin. The paraffin-embedded samples
were sectioned into 5 mM thin slices for the histochemical staining.
The fixed sections containing samples were deparaffinised in
xylene, rehydrated in an alcohol series, and stained with Mayer’s
Haematoxylin and Eosin Y (both from Sigma-Aldrich, Darmstadt,
Germany). After dehydration, the slides were mounted with
EntellanVR Neu (Merck; Darmstadt, Germany). The slides containing
the tissues were examined for morphological changes in the tis-
sues of the larvae exposed to the drugs and photographed using
a Nikon Microphot microscope (Nikon Microphot- FXA, Tokyo,
Japan). All the procedures were carried out at room temperature
unless stated otherwise.
Statistical analysis
The GraphPad Prism software (5.02) (GraphPad Software, La Jolla,
CA) was used to perform some of the statistical analyses. For stat-
istical analysis of the toxicity parameters, a two-tailed Fisher’s test
was used and p values below 0.05 were considered significant.
Results and discussion
Chemistry
Thiourea derivatives 3 and 4 were prepared starting from the
amino analogue of metronidazole 1 which was converted to iso-
thiocyanate 2 using thiophosgene under basic conditions.
Reaction either with 4-(2-aminoethyl) aniline or 4-(2-aminoethyl)
phenol in acetonitrile led to the thiourea-derivatives which were
then sulphamoylated with sulphamoyl chloride to give, respect-
ively, sulphamide 3 and sulphamate 4 (Scheme 1)24,25.
Compound 10 was prepared in a five-step synthesis starting
from metronidazole 5. Mesylation of 5 using methane sulphonyl
chloride under basic conditions led to compound 6. Reactions
with potassium thioacetate followed by oxidation and treatment
with phosgene allowed the formation of sulphonyl chloride 9.
Finally, compound 10 was obtained by treatment with a solution
ammonia in 1,4-dioxane at room temperature (Scheme 2)26.
CA inhibition assay
All compounds reported here were assayed as inhibitors of three
physiologically relevant CA isoforms, the cytosolic hCA I and II and
the transmembrane, tumour-associated hCA IX using the CO2
hydrase assay (Table 1)17. The clinically employed sulphonamide,
acetazolamide (AAZ, 5-acetamido-1,3,4- thiadiazole-2-sulphona-
mide), has been used as a standard in these measurements.
Compound 10 showed very weak inhibition potency against
the abundant cytosolic hCA I with a KI value of 6428 nM. The thio-
urea derivatives 3 and 4 demonstrated sub-micromolar inhibition
potency against all CA isoforms. Compound 4 showed the most
efficient binding to hCA II (KI ¼ 58.6 nM) with a selectivity ratio of
0.09 for inhibiting hCA II over hCA IX, explained by the influence
of the substitution on the benzene ring. Compound 10, the sul-
phonamide derivative of the sulphamide and sulphamate ana-
logues previously reported and biologically evaluated by our
group24, showed moderate binding efficacy towards hCA II (KI ¼
199.2 nM) and hCA IX (KI ¼ 147.3 nM). The better binding efficacy
of sulphonamide 10 compared to the sulphamide and sulphamate
compounds might be explained by higher stability under acidic
conditions, i.e. sulphonamide> sulphamide> sulphamate.
Evaluation of safety and toxicity of compounds 3, 4
and 10
Determination of inhibitor half maximal lethal
concentration (LC50)
The lethal effects of all three inhibitor compounds were concen-
tration dependent on the developing zebrafish embryos that were
exposed to the inhibitor for 5 d (Figure 1). None of the three
inhibitors exhibited any significant mortality in up to 1.5mM
Scheme 1. Synthesis of thioureas 3 and 4. Reagents and conditions: (i) thiophosgene, NaOH, CHCl3, 0 C-rt; (ii) 4-(2-aminoethyl) aniline, CH3CN, rt; (iii) NH2SO2Cl, DMA,
rt; (iv) 4-(2-aminoethyl) phenol, CH3CN, rt; (v) NH2SO2Cl, DMA, rt.
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concentration at the end of 5 d of exposure to the inhibitors.
Significant mortality of zebrafish larvae emerged at higher concen-
trations (>2mM), and the LC50 values at the end of five days
were 3mM for 3 and 2.6mM for 4 and 10. The half maximal lethal
concentrations of the inhibitors were higher compared to any tox-
icity and safety assessment studies that we have performed ear-
lier14–16, suggesting that these compounds can be further
developed as inhibitors of human CA I, CA II and CA IX.
Phenotypic analyses of zebrafish larvae treated with
inhibitor compounds
To assess toxic effects of the inhibitors on the developing zebrafish
larvae we analysed eight observable phenotypic parameters
namely: hatching, heartbeat, yolk sack utilisation, movement pat-
tern, body shape, swim bladder development, mortality and
oedema. The parameters were monitored using a stereo microscope
and observations were recorded for each group in comparison with
control embryos that were not treated with any of the compounds
or treated with 1% DMSO. The images in Figure 2 show the repre-
sentative larvae exposed to the compounds with concentrations
ranging from 75mM to 500 mM as compared to the control group
larvae. The microscopic examination did not show any of the
observable changes in the developing zebrafish embryos at these
concentrations and the embryos showed normal phenotypes
throughout the period of embryonic development from 2 to 5 dpf.
We further assessed the toxicity of compounds 3, 4 and 10
compounds in zebrafish larvae across the concentration range
12mM–3mM. Figure 3 presents plots of dose-dependent effects of
inhibitors on different parameters in treated larvae. The results
indicated that none of the inhibitors show significant toxic effects
at submillimolar range. Previous toxicity studies on hCA IX and
mycobacterial b-CA inhibitors showed significant effects on larval
mortality and observable phenotypic parameters in the concentra-
tion range of 50–300 mM14,16. Therefore, our present results show
that 3, 4 and 10 are less toxic in the zebrafish larval model.
Histochemical analysis
The effects of different concentrations of CA inhibitors on hist-
ology were studied by analysing the sections of 5 dpf zebrafish
larvae stained with haematoxylin and eosin (H & E). The stained
sagittal sections of both the inhibitor treated and control larvae
were compared by light microscopy. Representative images of
zebrafish larval sections are shown in Figure 4. The histological
examination revealed no damage to the tissues of the developing
zebrafish larvae. Even high concentrations (up to 2mM) showed
no apparent damage to the internal tissues, suggesting that these
compounds are safe and can be further developed as CA-specific
inhibitors for clinical use.
Analysis of swim pattern
During development, zebrafish embryos are easily affected by
chemical compounds compared to adult zebrafish or other animal
or cell models, and therefore are suitable for assessing the subtle
toxic effects of the chemicals14,22. To assess the subtle toxic
effects of the inhibitors, the swim pattern of the larvae was exam-
ined under the microscope during treatment with the CA inhibi-
tors. The swim pattern analysis showed no abnormal or ataxic
movement pattern in the larvae exposed to the inhibitors, up to
2mM concentration. However, a detailed analysis of the videos at
the end of 5 d of inhibitor exposure showed that the larvae of the
inhibitor treated groups (125mM) were not as active and tended
to remain at the sides of petri dish compared to the control group
larvae (Representative video of swim pattern treated with com-
pound 3: Supplementary Appendix A). The results of the current
study reveal that the larvae treated with 3, 4 and 10 become
slower while swimming as compared to the swim pattern of the
control group larvae. However, swim pattern of larvae treated
with 3, 4 and 10 was unlike the larvae treated with nitroimida-
zole-based inhibitors DTP338 and DTP348, which showed ataxic
movement pattern due to neurotoxicity at a concentration as low
as 100 mM14. Therefore, these novel thiourea and sulphonamide
derivatives can be considered safer for further preclinical charac-
terisation and development as potential drugs.
Scheme 2. Synthesis of sulphonamide 10. Reagents and conditions: (i) CH3SO2Cl, NEt3, DMAP, DCM, 0 C – rt; (ii) KSAc, DMF, rt; (iii) 35% H2O2-CH3COOH, rt; (iv) phos-
gene, cat. dry DMF, dry DCM, rt, (v) NH3 in 1,4 dioxane, benzene, rt.
Table 1. Inhibition data of compounds 3, 4 and 10 against hCA I, hCA II and





hCA I hCA II hCA IX KI hCA II/KI hCA IX
3 152.2 612.8 290.6 2.10
4 127.8 58.6 642.6 0.09
10 6428.4 199.2 147.3 1.35
AAZ 250 12.0 25 0.48
aAverage from three different assays, by a stopped flow technique (errors were
in the range of ± 5–10% of the reported values).
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Figure 1. The LC50 values of the tested CA inhibitor compounds. The LC50 doses for the inhibitors were determined based on the 50% mortality of the larvae at the
end of 5 d after the exposure of embryos to different concentrations of inhibitors: compound 3 (A), 4 (B) and 10 (C). The LC50 doses were determined after three inde-
pendent experiments with similar experimental conditions (for each compound N¼ 90).
Figure 2. The images of zebrafish larvae in control and inhibitor treated groups. Representative images of 2–5 dpf zebrafish larvae exposed to different concentrations
(75, 250 and 500lM) of compound 3, 4 and 10. The images of control group (not treated with inhibitors) and 1% DMSO treated zebrafish larvae show normal devel-
opment (n¼ 60).
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Figure 3. The effect of compounds 3, 4 and 10 CA inhibitors on the phenotypic parameters of the 5 dpf zebrafish larvae. The plot graphs of different phenotypic
abnormalities in (A) hatching, (B) oedema, (C) heartbeat (D) body shape and (E) yolk sac utilisation. For each concentration, n¼ 90. p< 0.05 by two-tailed
Fisher’s test.
Figure 4. Histochemical analyses of zebrafish larvae. Representative sagittal sections of an untreated zebrafish larva (A) or larva treated with 500lM of compound
3 (B), 4 (C) or 10 (D). The images presented here are selected from three independent groups of experiments.
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Conclusions
In conclusion, we have designed and synthesised thiourea and
sulphonamide derivative compounds with the potential to inhibit
human CA I, CA II and CA IX. These proteins which play important
pathophysiological roles in human diseases, such as well-known
role of CA IX in the progression of solid tumours, and those of CA
I and CA II in retinal and cerebral oedema, glaucoma, epilepsy
and altitude sickness. The inhibition kinetics of these inhibitors
were studied against recombinant human hCA I, hCA II and hCA
IX in vitro. Among these compounds, 4 was the most efficient
against hCA II (KI 58.6 nM). 10 inhibited human CA IX with KI
147.3 nM. The inhibition properties of these inhibitors against the
three hCA isoforms prompted us to test these drugs further for
their safety in a zebrafish larval model.
The toxicological evaluation indicated that these inhibitors
showed no adverse morphological changes nor did they cause
abnormal swim pattern at any sub-millimolar concentration. Taken
together, the results from both in vitro inhibition studies and toxi-
cological evaluation, we suggest that these inhibitors could be
developed into potential drugs targeting hCA I, hCA II and hCA IX
with no, or minimal, off-target effects.
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